Updates in the Treatment of Metastatic Urothelial Cancer

The past decade has seen a host of advancements in the management of metastatic urothelial carcinoma. Although efforts to identify novel systemic therapies are still ongoing, immune checkpoint inhibitors have become the preferred treatment option in this patient population. Recommendations for optimal treatment strategies—based on a patient’s eligibility for cisplatin—have been outlined in the NCCN Guidelines for Bladder Cancer in both the first-line and subsequent-line settings.